Thymalin

The clinical data supporting Thymalin originates almost entirely from a single research group based in St. Petersburg, Russia. The largest study conducted involved only 266 patients and was unblinded, non-randomized, and performed by the compound's own developers. There has been no independent replication of these findings in over 23 years, representing a significant evidence gap.

The speaker warns that Thymalin and Thymosin Alpha-1 are frequently and incorrectly used interchangeably, despite representing fundamentally different categories of evidence. Thymosin Alpha-1 is characterized as a well-validated compound with robust independent clinical data, while Thymalin is described as a crude extract with variable composition and no independent validation outside its creators. Consumers are advised to understand this distinction before purchasing either compound.

Thymalin is not a single defined peptide but rather a mixture of small proteins extracted from calf thymus glands, containing at least 12 different active fragments. Its composition varies depending on extraction method, tissue age, and processing temperature, meaning the product is inconsistent batch-to-batch. This variability fundamentally distinguishes it from a standardized synthetic peptide like Thymosin Alpha-1.